Trial Profile

A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizotinib (Primary) ; Temsirolimus; Vinblastine
Indications Anaplastic large cell lymphoma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms CRISP

Most Recent Events

25 Aug 2022 This trial has been completed in Ireland, according to European Clinical Trials Database record.
08 Feb 2020 Planned number of patients changed from 82 to 94.
01 Aug 2019 This trial has been suspended in Netherlands, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com